US regulator authorises Merck's Covid-19 pill

accreditation
0:00
play article
Subscribers can listen to this article
  • The FDA approved Pfizer's paxlovid pill a day earlier. 
  • Merck's Molnupiravir, taken within five days of symptom onset, is shown to reduce severe illness and death by 30 percent. 
  • It is not authorised for those under 18 nor recommended for pregnant women. 


On Thursday, the US Food and Drug Administration (FDA) authorised Merck's Covid-19 pill for high-risk.

"Today's authorisation provides an additional treatment option against the Covid-19 virus in the form of a pill that can be taken orally," said FDA scientist Patrizia Cavazzoni.

The pill developed by Merck, known as MSD outside the US and Canada, is taken within five days of symptom onset and has been shown to reduce Covid-19 hospitalisations and deaths by 30 percent among at-risk people.

Pfizer's pill reduced the same outcomes by 90 percent.

The FDA stressed in its statement that both the Pfizer and Merck pills should complement, rather than replace vaccines, that remain the frontline tool in the fight against the coronavirus.

While both treatments were found to be generally safe in clinical trials, more potential concerns have been raised about Merck's pill, called molnupiravir.

The FDA has not authorised Merck's pill for people under 18 because it may affect bone and cartilage growth.

It is not recommended for use in pregnant women because of the potential fetal harm, but doctors can still decide if the benefits outweigh the risks in individual cases.

Eight capsules of molnupiravir are taken orally for five days, for a total of 40 capsules.

The US has paid for 3.1 million courses of Merck's treatment and 10 million courses of Pfizer's.

Molnupiravir works by incorporating itself into the virus's genome, causing mutations that prevent viral replication.


Never miss a story. Choose from our range of newsletters to get the news you want delivered straight to your inbox.

We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For 14 free days, you can have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today. Thereafter you will be billed R75 per month. You can cancel anytime and if you cancel within 14 days you won't be billed. 
Subscribe to News24
Rand - Dollar
15.70
-0.3%
Rand - Pound
19.76
-0.7%
Rand - Euro
16.78
+0.2%
Rand - Aus dollar
11.14
-0.1%
Rand - Yen
0.12
+0.1%
Gold
1,854.63
-0.6%
Silver
22.03
-0.4%
Palladium
2,016.00
+0.4%
Platinum
951.00
-0.6%
Brent Crude
113.56
+0.1%
Top 40
61,176
0.0%
All Share
67,585
-0.2%
Resource 10
74,448
+0.1%
Industrial 25
72,681
+1.3%
Financial 15
15,434
-2.4%
All JSE data delayed by at least 15 minutes Iress logo
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.

LEARN MORE